Pregnancy and optimal care of HIV-infected patients

Clinical Infectious Diseases

Volumn 48, Issue 4, 2009, Pages 449-455

  Anderson, Brenna L ^a,b   Cu Uvin, Susan ^a  

^a BROWN UNIVERSITY   (United States)

^b Dept of Obstetrics and Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ANEMIA; BLOOD TOXICITY; BREAST FEEDING; CESAREAN SECTION; DELIVERY; DEVELOPED COUNTRY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABOR; LACTIC ACIDOSIS; LIVER TOXICITY; LOADING DRUG DOSE; MITOCHONDRIAL TOXICITY; PERINATAL PERIOD; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; RASH; REVIEW; RISK REDUCTION; TERATOGENICITY; UNITED STATES; VERTICAL TRANSMISSION;

BREAST FEEDING; CHEMOPREVENTION; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 58749097226     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596477     Document Type: Review

References (48)

1. Minkoff H, Nanda D, Menez R, Fikrig S. Pregnancies resulting in infants with acquired immunodeficiency syndrome or AIDS-related complex: follow-up of mothers, children, and subsequently born siblings. Obstet Gynecol 1987; 69:288-91.
2. Minkoff H, Nanda D, Menez R, Fikrig S. Pregnancies resulting in infants with acquired immunodeficiency syndrome or AIDS-related complex. Obstet Gynecol 1987; 69:285-7.
3. Centers for Disease Control and Prevention. Achievements in public health: reduction in perinatal transmission of HIV infection - United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2005; 55:592-7.
4. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341:394-402.
5. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 2001; 183:539-45.
6. + levels. J Acquir Immune Defic Syndr 1994; 7:718-26.
7. Rodriguez EM, Mofenson LM, Chang BH, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 1996; 10:273-82.
8. Matheson PB, Thomas PA, Abrams EJ, et al. Heterosexual behavior during pregnancy and perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS 1996; 10:1249-56.
9. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334:1617-23.
10. Minkoff H, Hershow R, Watts DH, et al. The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol 2003; 189:552-9.
11. Tai JH, Udoji MA, Barkanic G, et al. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis 2007; 196:1044-52.
12. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-94.
13. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2007. Available at: http://aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf. Accessed 9 June 2008.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 29 January 2008. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 9 June 2008.
15. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162:355.
16. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
17. Paton NI. Treatment interruption strategies: how great are the risks? Curr Opin Infect Dis 2008; 21:25-30.
18. Boskovic RM, Wide RB, Wolpin JP, Bauer DJP, Koren GM. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005; 65:807-11.
19. Polis CB, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin Infect Dis 2007; 44:1123.
20. Hershow RC, Riester KA, Lew J, et al. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. J Infect Dis 1997; 176:414.
21. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34(Suppl 1):S21-33.
22. Wohl DA, Pilcher CD, Evans S, et al. Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr 2004; 35:274-8.
23. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002; 78:58-9.
24. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177:557.
25. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002; 288:189-98.
26. Cunningham CK, Chaix M-L, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis 2002; 186:181.
27. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-86.
28. Zhang H, Dornadula G, Wu Y, Havlir D, Richman DD, Pomerantz RJ. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. J Virol 1996; 70:628-34.
29. Koup RA, Brewster F, Grob P, Sullivan JL. Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. AIDS 1993; 7:1181-4.
30. Dao H, Mofenson LM, Ekpini R, et al. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 2007; 197(Suppl 3):S42-55.
31. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-705.
32. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2008. Available at: http://aidsinfo.nih.gov/ contentfiles/PediatricGuidelines.pdf. Accessed 1 August 2008.
33. The Antiretroviral Pregnancy Registry. Available at: http://www.AP Registry.com. Accessed 1 August 2008.
34. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340:977-87.
35. Committee on Obstetric Practice. ACOG committee opinion scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Int J Gynaecol Obstet 2001; 73:279-81.
36. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-81.
37. Louis J, Landon MB, Gersnoviez RJ, et al. Perioperative morbidity and mortality among human immunodeficiency virus infected women undergoing cesarean delivery. Obstet Gynecol 2007; 110:385-90.
38. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359:1178-86.
39. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 343:982-91.
40. Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS 2005; 19:1865-75.
41. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access: recommendations for a public health approach. Geneva: World Health Organization, 2006.
42. World Health Organization Guidelines. Available at: http://www.who.int/ hiv/pub/guidelines/pmtctguidelines2006.pdf. Accessed 1 August 2008.
43. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs. formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: The Mashi Study. JAMA 2006; 296:794-805.
44. Becquet R, Bequet L, Ekouevi DK, et al. Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Cote d'Ivoire. PLoS Medicine 2007; 4:e17.
45. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369:1107-16.
46. Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai W-Y, Coovadia HM. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001; 15:379-87.
47. Gray GE, Saloojee H. Breast-feeding, antiretroviral prophylaxis, and HIV. N Engl J Med 2008; 359:189-91.
48. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 2008; 359:130-41.